vTv Therapeutics (NASDAQ:VTVT) received a $15.00 target price from investment analysts at Canaccord Genuity in a report released on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity’s target price points to a potential upside of 261.45% from the company’s current price.
Other analysts have also issued reports about the stock. Citigroup restated an “add” rating on shares of vTv Therapeutics in a research note on Wednesday, November 8th. Zacks Investment Research upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating and set a $6.00 price objective for the company in a research note on Saturday, September 16th. Finally, Stifel Nicolaus restated a “buy” rating and set a $12.00 price objective on shares of vTv Therapeutics in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. vTv Therapeutics currently has a consensus rating of “Buy” and an average target price of $14.10.
Shares of vTv Therapeutics (VTVT) traded down $0.28 during midday trading on Thursday, reaching $4.15. 118,039 shares of the company were exchanged, compared to its average volume of 34,386. vTv Therapeutics has a one year low of $3.57 and a one year high of $8.09.
In other news, Director Paul G. Savas acquired 15,000 shares of vTv Therapeutics stock in a transaction on Thursday, December 7th. The stock was acquired at an average cost of $4.56 per share, for a total transaction of $68,400.00. Following the purchase, the director now owns 81,781 shares in the company, valued at $372,921.36. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.80% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. bought a new stake in vTv Therapeutics during the 3rd quarter valued at about $481,000. State Street Corp grew its stake in shares of vTv Therapeutics by 2.1% in the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 1,976 shares during the period. Ameriprise Financial Inc. grew its stake in shares of vTv Therapeutics by 62.7% in the second quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock worth $1,313,000 after acquiring an additional 101,850 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of vTv Therapeutics by 4.8% in the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock worth $418,000 after acquiring an additional 2,900 shares during the period. Institutional investors and hedge funds own 10.42% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/01/14/vtv-therapeutics-vtvt-given-a-15-00-price-target-at-canaccord-genuity-updated-updated-updated.html.
About vTv Therapeutics
vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.